APUS · Apimeds Pharmaceuticals US, Inc.
$5.65
+5.00 (+764.84%)
At close · Jul 24
Going-concern doubt
— flagged May 26, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company’s ability to continue as a going concern. These condensed consolidated financial statements do not contain any adjustments that might result from the outcome of this uncertainty.”View the 10-Q filed May 26, 2026
Market Cap
$85.27M
Shares
15.09M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.65
Open$6.57
Day$5.44–6.87
52W$0.61–40.31
Avg vol 30d141K
Short int176K · 1.2% float · 1.0d
Short vol68%
DataMay 2025–Jul 2026
Filing10-Q · May 26
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 26, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.6 · elevated
Equity put/call 0.79
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−51%
below
Price vs 50-day avg
+380%
above
RSI (14)
93
overbought
MACD trend
Positive
52-week position
13%
near low
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+559%
trailing
6-month return
−69%
trailing
YTD return
−66%
this year
Relative strength
−76%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $12 — 200d above 50d
Institutional flow
Distributing
-14% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.16% of float · ▼ -24.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
6 holders — near 1-yr low, contrarian setup
Squeeze score
57
elevated · 0–100
Fundamentals
EPS growth
−206%
Y/Y
Free cash flow
$-9.0M
Balance sheet
$1.6M
net cash
Quant / Vol
risk profile
Volatility
785%
annualized · 1-yr
Max drawdown
−98%
past year
ATR
10.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−51%
Bearish
Price vs 50-day avg
+380%
Bullish
RSI (14)
93
Bearish
MACD trend
Positive
Bullish
52-week position
13%
Bearish
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $12 — 200d above 50d
Institutional flow
Distributing
-14% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.16% of float · ▼ -24.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
6 holders — near 1-yr low, contrarian setup
Price context
position in its 52-week range
52-wk low $1
Now $6 · 13%
52-wk high $40
vs 200-day avg -51%
vs 50-day avg +380%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
APUS
this stock
Apimeds Pharmaceuticals US, Inc.
|
$85.27M | -65.5% | — | — | 1.2% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$55.06B | +10.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.54B | +2.5% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.07B | -4.0% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| APUS | +756.1% | +558.5% | -69.5% | +527.8% | -65.6% |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | +757.7% | +557.8% | -75.8% | +528.9% | -73.8% |